SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
MYREXIS
(NQPK:MYRX Last Sale: .1 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQPK: (MYRX : $.1)
$4 million Market Cap at September 12, 2013
Employs 180.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
320 Wakara Way Research Report Earnings Snapshot - Last 05/10/16
Salt Lake City, UT 84108 Fact Sheet
Phone: (801) 214-7800 Financial Statements
Peer Comparison
Annual Reports

Adrian N. Hobden, CEO/Pres., W. Wayne Laslie, COO, Robert J. Lollini, CFO
Formed in a Spin-off by MYRIAD GENETICS INC (MYGN) June 30, 2009 to separate the molecular diagnostic business from the research and drug development businesses, 1-for-4. Agreed to acquire JAVELIN PHARMACEUTICALS INC (A:JAV) December 17, 2009 for $96 million in stock, 18 million shares, issuing 0.282 MYRX per JAV.
Historical Charts    Technical Analysis
No Historical Data available for MYRX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common MYRX $.1 $ 0 $.1 $.1 1,125 $.06 $3.02 42,506
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock $4,251

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex